Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | KDM1A | O60341 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | SAT1 | P21673 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
| ▸ | CPT2 | P23786 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22751206 | 0.98 | CYP2C19 (0.52) | CYP2C19CYP1A2KDM1AMEN1GLA | |
| SCHEMBL27294760 | 0.91 | CYP2C19 (0.50) | CYP2C19CYP1A2KDM1AMEN1GLA | |
| SCHEMBL21158602 | 0.84 | TSHR (0.54) | CYP2C19CYP1A2KDM1AMEN1GLA | |
| SCHEMBL20207809 | 0.81 | CYP2C19 (0.55) | CYP2C19CYP1A2KDM1AMEN1GLA | |
| SCHEMBL20804229 | 0.81 | CA12 (0.52) | CYP2C19CYP1A2MEN1KMT2ATSHR | |
| SCHEMBL15926000 | 0.80 | CYP2C19 (0.41) | CYP2C19CYP1A2KDM1AMEN1GLA | |
| SCHEMBL1834842 | 0.80 | TDP1 (0.43) | TSHRFFAR1CPT2TDP1 | |
| SCHEMBL1836223 | 0.80 | TDP1 (0.43) | TSHRFFAR1CPT2TDP1 | |
| SCHEMBL7863984 | 0.80 | TDP1 (0.43) | TSHRFFAR1CPT2TDP1 | |
| SCHEMBL19597731 | 0.79 | EPHX1 (0.50) | FFAR1CPT2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200270207-A1 | DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2020-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200270207-A1 | DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | DUT, TYMP, DPYD | CYP2C19 3154/4885CYP1A2 3141/4885KDM1A 1316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.